Outcomes in stage IIA versus stage IIB/III in the PALLAS trial [ABCSG-42/AFT-05/PrE0109/BIG-14-13])
A. DeMichele; A. C. Dueck; D. Hlauschek; M. Martin; H. Burstein; G. Pfeiler; N. Zdenkowski; A. Wolff · 2025 · Breast Cancer Research
WASTE classifies this as Negative / Null Result Report · AI classification, approximate
The study found no significant effect — useful as a negative control or null benchmark for your own design.
Abstract
Abstract Background The PALLAS trial investigated the addition of palbociclib to standard adjuvant endocrine therapy to reduce breast cancer recurrence. This pre-specified analysis was conducted to determine whether adjuvant palbociclib benefited patients diagnosed with lower risk stage IIA disease compared to those with higher stage disease. Methods PALLAS was an international, multicenter, randomized, open-label, phase III trial, representing a public–private partnership between Pfizer, the Austrian Breast Cancer Study Group, and the U.S. ALLIANCE Foundation. Patients diagnosed with stage II
Abstract by A. DeMichele; A. C. Dueck; D. Hlauschek; M. Martin; H. Burstein; G. Pfeiler; N. Zdenkowski; A. Wolff, Breast Cancer Research (2025) — licensed CC BY 4.0.
About to run something similar?
Run an AI Precheck on your own design to catch failure modes like this one before you spend the time. Your first desk check is free.
Related failures
Effects of Src on Proliferation and Invasion of Lung Cancer Cells
Negative / Null Result ReportSecretory Function of Kupffer Cells in Liver Cancer After Cryoablation
Negative / Null Result ReportEffect of antiangiogenic-based treatment and systemic inflammatory factors on outcomes in patients with BRAF v600-mutated metastatic colorectal cancer: a real-world study in Spain
Negative / Null Result ReportImpact of the interval between neoadjuvant immunochemotherapy and surgery on surgical–pathological outcomes in non-small cell lung cancer
Negative / Null Result ReportImpact of innate lymphoid cell type 2 in chronic lymphocytic leukemia on the function of treg and CD8+ T cells through IL-9
Negative / Null Result ReportAnti-ceramide antibody and sphingosine-1-phosphate as potential biomarkers of unresectable non-small cell lung cancer
WASTE indexes this work — it does not host or republish it. Failure-type classification is automated and approximate.
Metadata source: DOAJ · DOI 10.1186/s13058-024-01941-3